Literature DB >> 15746097

Presenilin-dependent gamma-secretase processing regulates multiple ERBB4/HER4 activities.

Gregory A Vidal1, Anjali Naresh, Luis Marrero, Frank E Jones.   

Abstract

Transmembrane receptors typically transmit cellular signals following growth factor stimulation by coupling to and activating downstream signaling cascades. Reports of proteolytic processing of cell surface receptors to release an intracellular domain (ICD) has raised the possibility of novel signaling mechanisms directly mediated by the receptor ICD. The receptor tyrosine kinase ERBB4/HER4 (referred to here as ERBB4) undergoes sequential processing by tumor necrosis factor-alpha converting enzyme and presenilin-dependent gamma-secretase to release the ERBB4 ICD (4ICD). Our recent data suggests that regulation of gene expression by the ERBB4 nuclear protein and the proapoptotic activity of ERBB4 involves the gamma-secretase release of 4ICD. To determine the role gamma-secretase processing plays in ERBB4 signaling, we generated an ERBB4 allele with the transmembrane residue substitution V673I (ERBB4-V673I). We demonstrate that ERBB4-V673I fails to undergo processing by gamma-secretase but retains normal cell surface signaling activity. In contrast to wild-type ERBB4, however, ERBB4-V673I was excluded from the nuclei of transfected cells and failed to activate STAT5A stimulation of the beta-casein promoter. These results support the contention that gamma-secretase processing of ERBB4 is necessary to release a functional 4ICD nuclear protein which directly regulates gene expression. We also demonstrate that 4ICD failed to accumulate within mitochondria of ERBB4-V673I transfected cells and the potent proapoptotic activity of ERBB4 was completely abolished in cells expressing ERBB4-V673I. Our results provide the first formal demonstration that proteolytic processing of ERBB4 is a critical event regulating multiple receptor signaling activities.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15746097     DOI: 10.1074/jbc.M412457200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  61 in total

1.  Phosphorylation of ErbB4 on Tyr1056 is critical for inhibition of colony formation by prostate tumor cell lines.

Authors:  Richard M Gallo; Ianthe Bryant; Rachael Fry; Eric E Williams; David J Riese
Journal:  Biochem Biophys Res Commun       Date:  2006-08-18       Impact factor: 3.575

2.  Increased trace amine-associated receptor 1 (TAAR1) expression is associated with a positive survival rate in patients with breast cancer.

Authors:  Aurelia Vattai; Elif Akyol; Christina Kuhn; Simone Hofmann; Helene Heidegger; Franz von Koch; Kerstin Hermelink; Rachel Wuerstlein; Nadia Harbeck; Doris Mayr; Christine Spitzweg; Bettina Toth; Sven Mahner; Udo Jeschke; Nina Ditsch
Journal:  J Cancer Res Clin Oncol       Date:  2017-04-13       Impact factor: 4.553

Review 3.  Substrate specificity of gamma-secretase and other intramembrane proteases.

Authors:  A J Beel; C R Sanders
Journal:  Cell Mol Life Sci       Date:  2008-05       Impact factor: 9.261

Review 4.  JAK-STAT pathway in carcinogenesis: is it relevant to cholangiocarcinoma progression?

Authors:  Olga V Smirnova; Tatiana Yu Ostroukhova; Roman L Bogorad
Journal:  World J Gastroenterol       Date:  2007-12-28       Impact factor: 5.742

Review 5.  Presenilin: RIP and beyond.

Authors:  Matthew R Hass; Chihiro Sato; Raphael Kopan; Guojun Zhao
Journal:  Semin Cell Dev Biol       Date:  2008-11-27       Impact factor: 7.727

6.  Neuregulin 1-activated ERBB4 interacts with YAP to induce Hippo pathway target genes and promote cell migration.

Authors:  Jonathan W Haskins; Don X Nguyen; David F Stern
Journal:  Sci Signal       Date:  2014-12-09       Impact factor: 8.192

Review 7.  Trafficking of receptor tyrosine kinases to the nucleus.

Authors:  Graham Carpenter; Hong-Jun Liao
Journal:  Exp Cell Res       Date:  2008-10-11       Impact factor: 3.905

Review 8.  ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer.

Authors:  David F Stern
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-05-03       Impact factor: 2.673

9.  Nuclear transit of the intracellular domain of the interferon receptor subunit IFNaR2 requires Stat2 and Irf9.

Authors:  Ashraf El Fiky; Pete Pioli; Arif Azam; Kiwon Yoo; Kent L Nastiuk; John J Krolewski
Journal:  Cell Signal       Date:  2008-03-21       Impact factor: 4.315

10.  Expression profiling of the ovarian surface kinome reveals candidate genes for early neoplastic changes.

Authors:  Tanja Pejovic; Nupur T Pande; Motomi Mori; Paulette Mhawech-Fauceglia; Christina Harrington; Solange Mongoue-Tchokote; Daniel Dim; Christopher Andrews; Amy Beck; Yukie Tarumi; Jovana Djilas; Fabio Cappuccini; Otavia Caballero; Jiaqi Huang; Samuel Levy; Alexia Tsiamouri; Joanna Cain; Grover C Bagby; Robert L Strausberg; Andrew J Simpson; Kunle O Odunsi
Journal:  Transl Oncol       Date:  2009-12       Impact factor: 4.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.